In summary, the present pan-cancer analysis, for the first time, offered a comprehensive understanding of the oncogenic role of GOLT1B across different cancers, demonstrating the potential of GOLT1B as a diagnostic biomarker and a target for cancer immunotherapy. This evidence concerns the gene GOLT1B and cancer.